Assessing Advancements in Early Cancer Detection: A Managed Care Review of New Diagnostics to Improve Outcomes

Assessing Advancements in Early Cancer Detection: A Managed Care Review of New Diagnostics to Improve Outcomes

Faculty

Tomasz M. Beer, MD, FACP
Deputy Director
Professor of Medicine, Hematology & Medical Oncology
Chief Medical Officer
Cancer Early Detection Advance Research Center (CEDAR)
OHSU Knight Cancer Institute
Portland, Oregon

Joel V. Brill, MD, FACP
Chief Medical Officer
Predictive Health
Paradise Valley, Arizona

Medical Writing and Editorial Support
Sara Fisher, PharmD
Medical Writer
Banner Medical, LLC
San Jose, California

Brittany Hoffmann-Eubanks, PharmD, MBA
Owner
Banner Medical, LLC
Frankfort, Illinois

Debra Gordon, MS
President
GordonSquared, Inc
Highland Park, Illinois
 

---

Program Description

Despite earlier detection and improved treatment, overall cancer deaths continue to escalate worldwide, and cancer remains the leading cause of death in the United States among those younger than 80 years. Considerable economic burden is associated with late-stage cancer as treatment costs can be up to twice those for early-stage disease. Only several cancers have guideline-recommended screening procedures; thus, many cancers are detected after symptoms appear and progress to late stages when treatment is more complex, and overall survival is reduced. Patient outcomes and overall economic and treatment burden may be significantly improved by earlier detection and diagnosis of cancer before it progresses. An array of technological advances in next-generation sequencing hold promise for future effective, early detection cancer screening tests for multiple cancer types. This activity will provide managed care professionals with an overview of trial data related to screening tests under development with a discussion of the potential impact if such technologies are incorporated into screening.

Target audience: Managed care pharmacists
Activity type: Application
Release date: November 16, 2020
Expiration date: November 16, 2021
Estimated time to complete activity: 2.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, the participant will be able to:
 

• Examine the health and economic burdens associated with early detection of cancer.
• Classify current recommendations for cancer screening and early detection.
• Analyze the recent and emerging published data associated with the novel multicancer detection blood tests.
• Explore the role of the managed care professional in integrating novel molecular diagnostic technologies for early cancer detection into treatment pathways and guidelines.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.5 contact hours (0.25 CEU) under the ACPE universal activity number 0290-0000-20-322-H01-P. The activity is available for CE credit through November 16, 2021.

Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the online article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Tomasz M. Beer, MD, FACP, has the following relevant financial relationships with commercial interests to disclose:
Grant/Research Support: Alliance Foundation Trials, Astellas Pharma, Boehringer Ingelheim, Corcept Therapeutics, Endocyte Inc, Freenome, GRAIL Inc, Harpoon Therapeutics, Janssen Research & Development, Medivation, Sotio, Theraclone Sciences/OncoResponse, Zenith Epigenetics

Consultant: Arvinas, Astellas Pharma, AstraZeneca Pharmaceuticals LP, Bayer HealthCare LLC, Bristol Myers Squibb, Constellation, GRAIL Inc, Novartis, Pfizer, Sanofi

Stock/Shareholder: Arvinas, Salarius Pharmaceuticals

Joel V. Brill, MD, FACP, has the following relevant financial relationships with commercial
interests to disclose:
Consultancies: Accomplish Health, Ambu, AnX Robotica, CapsoVision, Cernostics, Check Cap, Digma Medical, Diversatek, Dune Medical, Echosens, Endogastric Solutions, Erbe, evoEndo, Exact Sciences, Exalenz, Gala Therapeutics, Glaukos, Hello Heart, HyGIeaCare, Innovative Health Solutions, Insightec, Johnson & Johnson, Lumendi, Mainstay Medical, MaunaKea Technologies, Medtronic, Modify Health, MotusGI, Neuspera, Nuviera, Pacira, Penumbra, Perspectum, Proteus Digital Health, Reflexion, Respira Labs, Restech, Senseonics, SonarMD, StageZero Life Sciences, Sword Health, Tabula Rosa Health Care, Tusker Medical, UBC Pharma, Vertos Medical, WL Gore, Wright Medical

Debra Gordon, MS, has the following relevant financial relationships with commercial interests
to disclose:
Stockholder: Merck Sharp & Dohme Corp, AbbVie
Spouse: employed by AbbVie

Brittany Hoffmann-Eubanks, PharmD, MBA, and Sara Fisher, PharmD, have no relevant
financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Brianna Schauer, MBA, PMP; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy
According to the disclosure policy of The American Journal of Managed Care^® and Pharmacy Times Continuing Education™, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of Pharmacy Times Continuing Education™ to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Disclosure of Unapproved/Off-Label Use
The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and they are advised to consult prescribing information for these products.

The information provided in this CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of The American Journal of Managed Care^®, Pharmacy Times Continuing Education™, or any of the companies that provided commercial support for this CE activity.

Signed disclosures are on file at the office of The American Journal of Managed Care^®, Cranbury, New Jersey.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms